Enjoy complimentary customisation on priority with our Enterprise License!
The male hypogonadism market size is forecast to increase by USD 599.7 million at a CAGR of 4.5% between 2023 and 2028. The market is experiencing significant growth due to several key factors. The incidence of hypogonadism is on the rise, driven by an aging population and increasing awareness of the condition. Advanced treatment options, such as testosterone replacement therapy and hormonal therapies, are also contributing to market growth. Furthermore, the loss of patent exclusivities for several major drugs is increasing generic competition, leading to price erosion and increased accessibility of treatments for patients. These trends are expected to continue, making the market a promising area for investment and innovation in the healthcare sector.
Male Hypogonadism refers to a condition where the testes or sex glands do not produce enough testosterone, the primary male sex hormone. This condition can lead to various symptoms such as testicular issue, muscle mass development and body hair growth deficiency, voice deepening delay, and breast tissues growth. The causes of male hypogonadism can be due to issues in the hypothalamus or pituitary gland, which control the production of Gonadotropin-Releasing Hormones (GnRH). The market for Male Hypogonadism Therapy is expected to grow due to the increasing incidence of testosterone deficiency in men, particularly those with conditions like Type 2 diabetes, cardiovascular disease, metabolic syndrome, and Alzheimer's disease.
Furthermore, these conditions are known to affect the quality of life and can lead to premature death. Technological innovation in hormone delivery systems and drug development is driving the growth of the market. Therapies like GnRH therapy are becoming increasingly popular due to their effectiveness in stimulating the production of testosterone. The market is expected to witness significant growth in the coming years due to the increasing awareness of the condition and the availability of effective treatments. The market for Male Hypogonadism Therapy is segmented based on therapy type, drug delivery type, and end-users. The market is expected to grow at a steady pace due to the increasing demand for effective treatments for testosterone deficiency and the growing awareness of the condition.
Additionally, the market is also expected to witness significant growth due to the increasing prevalence of conditions like Type 2 diabetes, cardiovascular disease, metabolic syndrome, and Alzheimer's disease, which are known to be associated with testosterone deficiency.
The market research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in "USD million" for the period 2024-2028, as well as historical data from 2018-2022 for the following segments.
The klinefelters syndrome segment is estimated to witness significant growth during the forecast period. Testosterone deficiency, also known as hypogonadism, is a condition characterized by the impairment of the sex glands' function, leading to a decrease in sex hormones such as testosterone. This condition can result in various symptoms including muscle mass development and body hair growth reduction, breast tissues growth, voice deepening difficulties, and testicular issues. The hypothalamus and pituitary gland, key organs in the endocrine system, regulate the production of testosterone. Hypogonadism can significantly impact an individual's quality of life, leading to therapy and drug delivery methods to restore hormonal balance. Andropause, a term similar to menopause for men, is a natural part of aging, but testosterone deficiency can also be caused by gonad deficiency, diabetes, obesity, lifestyle changes such as smoking and drinking habits, and high stress levels.
Furthermore, estrogen and androgen imbalances can also contribute to the after-effects of testosterone deficiency, leading to complications such as infertility rates, type 2 diabetes, cardiovascular disease, and premature death. Technological innovation in hormone development and delivery methods, including generics, offers hope for those suffering from this condition. Masculine growth during puberty and sperm production are essential functions of testosterone, making its restoration crucial for overall health and wellbeing.
Get a glance at the market share of various segments Request Free Sample
The klinefelters syndrome segment was valued at USD 881.70 million in 2018 and showed a gradual increase during the forecast period.
North America is estimated to contribute 47% to the growth of the global market during the forecast period. Technavio's analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.
For more insights on the market share of various regions Request Free Sample
Male hypogonadism refers to the condition where the testes produce insufficient testosterone, the primary male sex hormone. This deficiency can lead to various symptoms such as muscle mass development and body hair growth reduction, breast tissue growth, voice deepening difficulties, and testicular issues. The hypothalamus and pituitary gland, which regulate the production of sex hormones from the sex glands, may be responsible for this condition. Testosterone deficiency can significantly impact a man's quality of life, leading to therapy and drug delivery methods to restore hormonal balance. Serum testosterone levels can indicate the severity of the condition, and andropause, a term used for age-related testosterone decline, can also contribute to hypogonadism.
Further, factors such as diabetes, obesity, lifestyle changes like smoking and drinking habits, and stress levels can exacerbate testosterone deficiency. Estrogen and androgen imbalances can also have after effects, including infertility rates and increased risk for conditions like type 2 diabetes, cardiovascular disease, and premature death. Awareness and technological innovation have led to the development of generics and advanced hormone therapies for masculine growth and development, even during puberty. Sperm production can also be affected, impacting fertility. Overall, addressing testosterone deficiency is crucial for maintaining optimal health and well-being.
Our researchers analyzed the data with 2023 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.
An increase in incidence of hypogonadism is the key driver of the market. Hypogonadism, a disorder characterized by deficient gonadotropin-releasing hormones (GnRH) or androgen resistance, affects an estimated 4-5 million men in the US annually. Prevalence ranges from 2.1% to 12.8% in middle-aged to older European and American men, with an incidence of 12 new cases per 1,000 person-years. Metabolic syndrome, obesity, and type 2 diabetes mellitus increase the risk of hypogonadism. Approximately 10-12% of affected men undergo testosterone replacement therapy (TRT). Hypogonadal men exhibit an increased risk of depressive illness and Alzheimer's disease. Age-related testosterone decline, affecting 30% of men over 55, is a common form of hypogonadism. This condition results from hypothalamic-pituitary axis dysfunction and testicular impairment.
Additionally, Clinical research focuses on developing alternative therapies, including topical gels, injectables, and transdermal patches, for TRT. Hypogonadism is also associated with infertility, and various chronic disorders, such as Klinefelter Syndrome, Kallmann Syndrome, and pituitary disorders, can contribute to its development.
The advancements in treatment options is the upcoming trend in the market. Male hypogonadism, a disorder characterized by deficient gonadotropin-releasing hormones (GnRH) or androgen resistance, affects various aspects of male health, including testosterone level, spermatozoa production, and metabolic function. The incidence of male hypogonadism increases with age and chronic disorders such as metabolic syndrome, Alzheimer's disease, and Klinefelter's and Kallmann syndromes. companies in the market are focusing on expanding their product offerings and market reach through strategic collaborations and acquisitions. For instance, in April 2021, Clarus Therapeutics Inc. Announced a merger agreement with Blue Water Acquisition Corporation to accelerate the commercialization of oral testosterone replacement therapy and fund the development of new androgen and metabolic therapies.
Additionally, this strategic move will enable the company to bring capital funding to expand its portfolio and invest in research and development of innovative treatments for male hypogonadism. Other therapies for male hypogonadism include testosterone replacement through topical gels, injectables, and transdermal patches. The geriatric population and those with pituitary disorders are major targets for these therapies due to their higher prevalence of hypogonadism. Clinical research is ongoing to explore the potential of new therapies for male hypogonadism, including enzyme-targeted treatments for androgen resistance and hormone level modulation.
The loss of patent exclusivities and increasing generic competition is a key challenge affecting the market growth. Male hypogonadism, a disorder characterized by deficient gonadotropin-releasing hormones (GnRH) or androgen resistance, affects various aspects of reproductive health, including testosterone level and spermatozoa production. Metabolic syndrome, Alzheimer's disease, and chronic disorders are associated with an increased incidence of this condition. Hypothalamic-pituitary axis dysfunction and enzyme abnormalities contribute to the development of male hypogonadism. Gonadotropin-releasing hormone therapy and testosterone replacement are common treatments. Testosterone replacement is available in various forms, such as topical gels, injectables, and transdermal patches. In the US, prescription testosterone primarily consists of topically applied treatments, including gels and patches. Injectable products like Aveed and Testopel, which are implanted under the skin by a physician, are also FDA-approved.
Additionally, clinical research is ongoing to address the unmet needs of male hypogonadism, including the treatment of infertility and the management of associated conditions like Klinefelters Syndrome, Kallmann Syndrome, and pituitary disorders. The expiry of patents on these therapies may lead to a growth in the availability of cost-effective generic drugs, impacting the market dynamics. The geriatric population is a significant target demographic due to the higher prevalence of chronic disorders associated with male hypogonadism.
The market forecasting report includes the adoption lifecycle of the market, covering from the innovator's stage to the laggard's stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their market growth analysis strategies.
Customer Landscape
Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market.
AbbVie Inc. - The company offers male hypogonadism treatment, through its Testosterone Gel.
The market research and growth report includes detailed analyses of the competitive landscape of the market and information about key companies, including:
Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.
Male hypogonadism refers to a condition where the sex glands, specifically the testes, fail to produce enough testosterone, the primary male sex hormone. This deficiency can lead to various symptoms such as muscle mass development and body hair growth reduction, breast tissues growth, voice deepening issues, and testicular issues. The condition can be caused by problems in the hypothalamus or pituitary gland, which control the production of sex hormones. Male hypogonadism can significantly impact a man's quality of life, leading to symptoms such as infertility, low energy levels, and mood swings.
Further, factors such as diabetes, obesity, smoking, drinking habits, and stress levels can contribute to the development of this condition. The market for male hypogonadism therapy is growing, with a focus on developing new drug delivery methods and technological innovations. Serum testosterone replacement therapy is a common treatment, and the market for generics is also expanding. However, the after-effects of long-term hormone therapy are still being researched. Male hypogonadism is also linked to conditions such as type 2 diabetes, cardiovascular disease, and premature death. Raising awareness about the condition and its causes is essential to encourage early diagnosis and treatment.
In conclusion, sex hormones, including testosterone and estrogen, play a crucial role in masculine growth and development, from puberty to old age. Understanding the complex relationship between these hormones and their impact on health is essential to developing effective therapies and improving the quality of life for those affected by male hypogonadism.
Market Scope |
|
Report Coverage |
Details |
Page number |
140 |
Base year |
2023 |
Historic period |
2018-2022 |
Forecast period |
2024-2028 |
Growth momentum & CAGR |
Accelerate at a CAGR of 4.5% |
Market growth 2024-2028 |
USD 599.7 million |
Market structure |
Concentrated |
YoY growth 2023-2024(%) |
4.23 |
Regional analysis |
North America, Europe, Asia, and Rest of World (ROW) |
Performing market contribution |
North America at 47% |
Key countries |
US, Germany, China, UK, and Canada |
Competitive landscape |
Leading Companies, Market Positioning of Companies, Competitive Strategies, and Industry Risks |
Key companies profiled |
AbbVie Inc., Aytu BioPharma Inc., Bayer AG, Bio Techne Corp., Diurnal Ltd., Eli Lilly and Co., Endo International Plc, Ferring BV, IBSA Institute Biochimique SA, Lipocine Inc., Merck and Co. Inc., Perrigo Co. Plc, Pfizer Inc., and Teva Pharmaceutical Industries Ltd. |
Market dynamics |
Parent market analysis, market growth inducers and obstacles, market forecast, fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, market condition analysis for the forecast period |
Customization purview |
If our market report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
We can help! Our analysts can customize this market research report to meet your requirements. Get in touch
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Type
7 Customer Landscape
8 Geographic Landscape
9 Drivers, Challenges, and Opportunity/Restraints
10 Competitive Landscape
11 Competitive Analysis
12 Appendix
Get the report (PDF) sent to your email within minutes.
Get lifetime access to our
Technavio Insights
Quick Report Overview:
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.